M M Widlak1,2, C L Thomas3, M G Thomas4, C Tomkins3, S Smith5, N O'Connell1, S Wurie1, L Burns1, C Harmston6, C Evans6, C U Nwokolo1, B Singh7, R P Arasaradnam1,2,8. 1. Department of Gastroenterology, University Hospitals Coventry and Warwickshire, Coventry, UK. 2. Medical School, University of Warwick, Coventry, UK. 3. Department of Biochemistry, University Hospitals Coventry and Warwickshire, Coventry, UK. 4. Medical School, University of Oxford, Oxford, UK. 5. Midlands and North West Bowel Cancer Screening Hub, University Hospitals Coventry and Warwickshire, Coventry, UK. 6. Department of Colorectal Surgery, University Hospitals Coventry and Warwickshire, Coventry, UK. 7. Department of Colorectal Surgery, University Hospitals of Leicester, Leicester, UK. 8. Applied Biological and Experimental Sciences, University of Coventry, Coventry, UK.
Abstract
BACKGROUND: The diagnosis of colorectal cancer (CRC) can be difficult as symptoms are variable with poor specificity. Thus, there is a quest for simple, non-invasive testing that can help streamline those with significant colonic pathology. AIM: To assess using faecal immunochemical test for haemoglobin (FIT) or faecal calprotectin (FCP) to detect CRC and adenoma in symptomatic patients referred from primary care. METHODS: A total of 799 referred for urgent lower gastrointestinal investigations were prospectively recruited. Of these, 430 completed colonic investigations and returned stool samples, and were included in the final statistical analysis. Faecal immunochemical test for haemoglobin was performed on HM-JACKarc analyser (Kyowa Medex, Tokyo, Japan), and FCP by the EliA Calprotectin immunoassay (Thermo Fisher Scientific, Waltham, United States). RESULTS: The negative predictive value (NPV) using FIT alone or both markers (FIT and FCP) in combination was similar at 99% for CRC, with a sensitivity and specificity of 84% and 93%, respectively. FIT measurements were significantly higher in left-sided colonic lesions compared with the right side; 713 vs. 94; P = 0.0203). For adenoma, the NPV using FIT alone, or both markers (FIT and FCP) in combination, was similar at 94% with a sensitivity and specificity of 69% and 56%, respectively. CONCLUSIONS: Undetectable faecal immunochemical test for haemoglobin is sufficiently sensitive to exclude colorectal cancer, with higher values in left-sided lesions. FCP in combination does not appear to provide additional diagnostic information. Further studies to determine the health economic benefits of implementing faecal immunochemical test for haemoglobin in primary care are required.
BACKGROUND: The diagnosis of colorectal cancer (CRC) can be difficult as symptoms are variable with poor specificity. Thus, there is a quest for simple, non-invasive testing that can help streamline those with significant colonic pathology. AIM: To assess using faecal immunochemical test for haemoglobin (FIT) or faecal calprotectin (FCP) to detect CRC and adenoma in symptomatic patients referred from primary care. METHODS: A total of 799 referred for urgent lower gastrointestinal investigations were prospectively recruited. Of these, 430 completed colonic investigations and returned stool samples, and were included in the final statistical analysis. Faecal immunochemical test for haemoglobin was performed on HM-JACKarc analyser (Kyowa Medex, Tokyo, Japan), and FCP by the EliA Calprotectin immunoassay (Thermo Fisher Scientific, Waltham, United States). RESULTS: The negative predictive value (NPV) using FIT alone or both markers (FIT and FCP) in combination was similar at 99% for CRC, with a sensitivity and specificity of 84% and 93%, respectively. FIT measurements were significantly higher in left-sided colonic lesions compared with the right side; 713 vs. 94; P = 0.0203). For adenoma, the NPV using FIT alone, or both markers (FIT and FCP) in combination, was similar at 94% with a sensitivity and specificity of 69% and 56%, respectively. CONCLUSIONS: Undetectable faecal immunochemical test for haemoglobin is sufficiently sensitive to exclude colorectal cancer, with higher values in left-sided lesions. FCP in combination does not appear to provide additional diagnostic information. Further studies to determine the health economic benefits of implementing faecal immunochemical test for haemoglobin in primary care are required.
Authors: Craig Mowat; Jayne Digby; Judith A Strachan; Rebecca K McCann; Francis A Carey; Callum G Fraser; Robert Jc Steele Journal: Ann Clin Biochem Date: 2021-01-21 Impact factor: 2.057
Authors: Brian D Nicholson; Tim James; James E East; David Grimshaw; Maria Paddon; Steve Justice; Jason L Oke; Brian Shine Journal: Frontline Gastroenterol Date: 2018-10-09
Authors: S Mashlab; P Large; W Laing; O Ng; M D'Auria; D Thurston; S Thomson; A G Acheson; D J Humes; A Banerjea Journal: Ann R Coll Surg Engl Date: 2018-03-15 Impact factor: 1.891
Authors: James L Turvill; Daniel Turnock; Dan Cottingham; Monica Haritakis; Laura Jeffery; Annabelle Girdwood; Tom Hearfield; Alex Mitchell; Ada Keding Journal: Br J Gen Pract Date: 2021-07-29 Impact factor: 6.302
Authors: Marie Westwood; Shona Lang; Nigel Armstrong; Sietze van Turenhout; Joaquín Cubiella; Lisa Stirk; Isaac Corro Ramos; Marianne Luyendijk; Remziye Zaim; Jos Kleijnen; Callum G Fraser Journal: BMC Med Date: 2017-10-24 Impact factor: 8.775
Authors: Vivian Weiwen Xue; Simon Siu Man Ng; Wing Wa Leung; Brigette Buig Yue Ma; William Chi Shing Cho; Thomas Chi Chuen Au; Allen Chi Shing Yu; Hin Fung Andy Tsang; Sze Chuen Cesar Wong Journal: Front Genet Date: 2018-05-15 Impact factor: 4.599
Authors: Michael McFarlanE; Ella MozdiaK; Emma Daulton; Ramesh Arasaradnam; James Covington; Chuka Nwokolo Journal: PLoS One Date: 2020-07-31 Impact factor: 3.240